Display options
Cite
Su T, Bai JX, Chen YJ, et al. An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Front Pharmacol. 2017;8:227doi: 10.3389/fphar.2017.00227.
Su, T., Bai, J. X., Chen, Y. J., Wang, X. N., Fu, X. Q., Li, T., Guo, H., Zhu, P. L., Wang, Y., & Yu, Z. L. (2017). An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Frontiers in pharmacology, 8227. https://doi.org/10.3389/fphar.2017.00227
Su, Tao, et al. "An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling ." Frontiers in pharmacology vol. 8 (2017): 227. doi: https://doi.org/10.3389/fphar.2017.00227
Su T, Bai JX, Chen YJ, Wang XN, Fu XQ, Li T, Guo H, Zhu PL, Wang Y, Yu ZL. An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling . Front Pharmacol. 2017 Apr 28;8:227. doi: 10.3389/fphar.2017.00227. eCollection 2017. PMID: 28503147; PMCID: PMC5408070.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2017 Apr 28;8:227. doi: 10.3389/fphar.2017.00227. eCollection 2017.

An Ethanolic Extract of Ampelopsis Radix Exerts Anti-colorectal Cancer Effects and Potently Inhibits STAT3 Signaling .

Frontiers in pharmacology

Tao Su, Jing-Xuan Bai, Ying-Jie Chen, Xin-Ning Wang, Xiu-Qiong Fu, Ting Li, Hui Guo, Pei-Li Zhu, Yue Wang, Zhi-Ling Yu

Affiliations

  1. Consun Chinese Medicines Research Centre for Renal Diseases, School of Chinese Medicine, Hong Kong Baptist UniversityKowloon Tong, China.
  2. Center for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist UniversityHong Kong, China.
  3. HKBU Shenzhen Research Institute and Continuing EducationShenzhen, China.

PMID: 28503147 PMCID: PMC5408070 DOI: 10.3389/fphar.2017.00227

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. Signal transducer and activator of transcription 3 (STAT3) signaling is constantly activated in CRC, and has been proposed as a pathogenic factor and a therapeutic target of CRC. Ampelopsis Radix (AR), a traditional Chinese medicinal herb, possesses low toxicity and has long been used clinically for the treatment of cancers including CRC. Some constituents of AR have been reported to exert anti-cancer properties by targeting STAT3. However, the anti-CRC mode and mechanism of action of AR have not been fully elucidated. Here, we investigated the involvement of STAT3 signaling in the anti-CRC effects of AR. Results showed that AR reduced cell viability, induced cell apoptosis, and suppressed cell migration and invasion in human HCT-116 and SW480 CRC cells. Mechanistic studies showed that AR potently suppressed STAT3 and Src phosphorylation, and inhibited STAT3 nuclear localization in cultured CRC cells. AR also downregulated the expression of STAT3 target genes Mcl-1, Bcl-xL, and MMP-2 that are involved in cell survival and mobility. Moreover, the cytotoxic effect of AR was diminished by overexpressing STAT3C, a persistent active variant of STAT3. In conclusion, AR exerted anti-CRC effects

Keywords: Ampelopsis Radix; STAT3; apoptosis; colorectal cancer; invasion; migration

References

  1. Cell Signal. 2015 Feb;27(2):293-305 - PubMed
  2. Anticancer Res. 2012 Dec;32(12):5353-61 - PubMed
  3. Mol Interv. 2011 Feb;11(1):18-26 - PubMed
  4. Mol Med Rep. 2015 May;11(5):3722-8 - PubMed
  5. J Dairy Sci. 2014 Feb;97(2):672-8 - PubMed
  6. World J Gastroenterol. 2016 Apr 21;22(15):3952-61 - PubMed
  7. Mol Med Rep. 2015 Aug;12(2):2107-13 - PubMed
  8. Nature. 2016 Dec 12;:null - PubMed
  9. Biochem Pharmacol. 2014 Feb 1;87(3):424-34 - PubMed
  10. Ther Adv Med Oncol. 2011 Jan;3(1):43-52 - PubMed
  11. J Clin Pathol. 2005 Aug;58(8):833-8 - PubMed
  12. Oncotarget. 2016 Aug 23;7(34):54702-54713 - PubMed
  13. Cell Death Dis. 2017 Jan 5;8(1):e2534 - PubMed
  14. Oncologist. 2007 Dec;12(12):1443-55 - PubMed
  15. Exp Dermatol. 2014 Nov;23(11):855-7 - PubMed
  16. Oncotarget. 2016 Mar 15;7(11):12917-26 - PubMed
  17. Surg Clin North Am. 2015 Oct;95(5):979-89 - PubMed
  18. PLoS One. 2015 May 08;10(5):e0123478 - PubMed
  19. Cancer Immunol Res. 2017 Feb;5(2):94-99 - PubMed
  20. Oncol Rep. 2014 Aug;32(2):821-8 - PubMed
  21. Breast Cancer Res Treat. 2009 Oct;117(3):505-15 - PubMed
  22. Eur J Immunol. 2016 Feb;46(2):269-80 - PubMed
  23. Biochim Biophys Acta. 2013 Mar;1830(3):2619-28 - PubMed
  24. PLoS One. 2013 Sep 26;8(9):e75414 - PubMed
  25. PLoS One. 2016 Aug 09;11(8):e0160125 - PubMed
  26. Anticancer Res. 1998 Jan-Feb;18(1A):119-24 - PubMed
  27. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  28. Cell. 1999 Aug 6;98(3):295-303 - PubMed
  29. J Clin Pathol. 2007 Feb;60(2):173-9 - PubMed
  30. World J Gastroenterol. 2004 Jun 1;10(11):1569-73 - PubMed
  31. Planta Med. 2010 Aug;76(11):1118-31 - PubMed
  32. Hepatol Res. 2015 Dec;45(13):1283-91 - PubMed
  33. Biomed Res Int. 2016;2016:6896024 - PubMed
  34. Cancer Res. 2011 Dec 1;71(23 ):7226-37 - PubMed
  35. Exp Cell Res. 2013 Dec 10;319(20):3238-50 - PubMed
  36. Oxid Med Cell Longev. 2015;2015:181260 - PubMed
  37. Atherosclerosis. 2016 May;248:179-89 - PubMed
  38. Nat Rev Drug Discov. 2007 Feb;6(2):115-20 - PubMed

Publication Types